January 06, 2023 -- Today, the U.S. Food and Drug Administration approved Leqembi (lecanemab-irmb) via the Accelerated Approval pathway for the treatment of Alzheimer’s disease. Leqembi is the second of a new category of……
November 02, 2022--Gilead Sciences, Inc. (Nasdaq: GILD) today announced that the U.S. Food and Drug Administration (FDA) has approved the supplemental new drug application (sNDA) for Vemlidy® (tenofovir alafenamide) 25 m……
Oct. 20, 2022, AbbVie (NYSE: ABBV) today announced the acquisition of DJS Antibodies Ltd ("DJS"), Under the terms of the agreement, AbbVie will pay DJS shareholders approximately $255 million in cash at cl……
Oct. 27, 2022 (GLOBE NEWSWIRE) -- Biogen Inc. (Nasdaq: BIIB) today announced that the U.S. Food and Drug Administration (FDA) has extended the review period of the new drug application (NDA) for tofersen by three months.……
Pfizer (PFE.US) 's $22.6 billion acquisition of Biohaven (BHVN.US) will be completed on October 3, according to the Securities and Exchange Commission.Pfizer announced plans to acquire Biohaven in May. After the acqu……
September 5, 2022 --AstraZeneca’s Forxiga (dapagliflozin), a sodium-glucose cotransporter 2 (SGLT2) inhibitor, has been approved in China to reduce the risk of sustained estimated glomerular filtration rate (eGFR) declin……
Copyright Nanjing Dorra Pharmaceutical Technology Co.,Ltd. @ 2018 China All Rights Reserved 苏ICP备12056923号-1
Tel: 025-82232955 025-82232966
Fax:025-82232933 025-82232944
E-mail: info@dorrapharma.com
